Akero Therapeutics price target lowered to $78 from $80 at Citi

Citi lowered the firm’s price target on Akero Therapeutics (AKRO) to $78 from $80 and keeps a Buy rating on the shares. The company reported Q1 earnings after it revealed clinical data from its Phase 2b SYMMETRY trial at the European Association for the Study of the Liver conference last week, the analyst tells investors in a research note. The firm says the detailed data showed that efruxifermin treatment led to improvements on multiple noninvasive measures of liver fibrosis, adding on to 96-week topline liver biopsy data released earlier this year.